Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with drug-trial data and cash-runway tables can drain hours. Sagimet Biosciences’ 10-K alone layers complex R&D footnotes over dense risk factors tied to its FASN program. If you are searching “Sagimet Biosciences SEC filings explained simply” or wondering how Form 4 insider trades may signal management’s confidence, you have likely met this challenge.
Stock Titan solves it. Our AI reads every Sagimet Biosciences annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event the moment EDGAR posts them. It then delivers concise, plain-English summaries that highlight R&D spend, denifanstat trial milestones, and liquidity updates—exactly what analysts look for. Real-time alerts flag “Sagimet Biosciences insider trading Form 4 transactions” so you can track executive stock moves without sifting through PDFs. Need quick answers? Ask, “Where is Sagimet Biosciences’ proxy statement executive compensation?” and our platform directs you to the page and provides context.
Investors use these insights to:
- Compare quarter-over-quarter clinical expenses across business segments
- Monitor “Sagimet Biosciences Form 4 insider transactions real-time” for buying or selling patterns
- Decode 8-K disclosures on trial results or financing agreements within minutes
Whether you are analysing a fresh 10-Q or revisiting a past 10-K, Stock Titan delivers comprehensive coverage, AI-powered summaries, and expert analysis so you can understand Sagimet Biosciences filings quickly and act with confidence.
Sagimet Biosciences Inc. (SGMT) reported an insider transaction by a director and Executive Chairman. On 11/20/2025, the reporting person sold 37,688 shares of Series A common stock in an open-market sale coded as "S." The weighted average sale price was $7.6942 per share, with individual trades executed between $7.27 and $8.15.
After this transaction, the insider beneficially owned 81,005 shares of Sagimet Biosciences common stock in direct ownership. The sale was carried out under a Rule 10b5-1 trading plan adopted on August 21, 2025, which is a pre-arranged plan designed to allow insiders to sell shares according to predetermined instructions.
Sagimet Biosciences (SGMT) furnished an update via Form 8-K. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and provided an updated investor presentation. Both materials are included as Exhibits 99.1 and 99.2 and are incorporated by reference.
The company noted that the press release and investor presentation are being furnished, not filed, under the Exchange Act. Representatives may use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) reported Q3 2025 results showing a net loss of $12.9 million as it advances its fatty acid synthase inhibitor programs. Operating expenses were $14.3 million, with research and development of $9.7 million, down 23% year over year on lower Phase 3 denifanstat clinical costs, partly offset by a $2.5 million up-front CMO license fee and new early‑stage studies. General and administrative expenses were $4.6 million.
Liquidity remained solid with cash, cash equivalents and marketable securities of $125.5 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company established a $75.0 million at‑the‑market program in August 2025 with no sales in the quarter. Accumulated deficit was $336.8 million.
Program updates: denifanstat met primary and multiple secondary endpoints in Phase 2b MASH and a Phase 1 PK trial combining denifanstat with resmetirom began in September 2025. In acne, Sagimet’s partner reported Phase 3 success in China and plans an NDA submission. Sagimet also began a Phase 1 trial of TVB‑3567 for acne in June 2025.
Sagimet Biosciences (SGMT)
The RSUs vest in four equal annual installments following November 4, 2025. The option vests over 48 equal monthly installments following November 4, 2025 and has an expiration date of 11/03/2035. After these grants, 193,581 Series A Common shares were beneficially owned directly, and 13,367 options were held.
Sagimet Biosciences (SGMT) furnished an updated investor presentation as Exhibit 99.1 to a Form 8-K. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished and are not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth in a future filing.
Representatives may use the updated presentation in meetings with investors from time to time. The filing is an informational Reg FD update and does not announce a transaction or financial results.
Sagimet Biosciences Inc. (Series A Common Stock, CUSIP 786700104) is the subject of an amended Schedule 13G filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0 shares and 0% of the Series A common stock and reports no sole or shared voting or dispositive power. The filing includes the issuer address and identifies the filers and their Delaware organization or U.S. citizenship where applicable. The submission contains a certification that the shares were not acquired to influence control of the issuer.
Sagimet Biosciences, Inc. reported the entry into a material definitive agreement on
Sagimet Biosciences Inc. filed a prospectus supplement to offer up to $75.0 million of Series A common stock through an "at-the-market" sales agreement with Leerink Partners. The company’s Series A common stock trades on Nasdaq under the symbol SGMT and the last reported sale price referenced was $9.58 per share on August 13, 2025. Net proceeds are intended to advance development of denifanstat and other FASN inhibitors, for R&D, working capital and general corporate purposes.
The supplement highlights clinical progress: denifanstat met both primary and multiple secondary endpoints in a Phase 2b FASCINATE-2 MASH trial (statistically significant histologic and MRI-PDFF results) and received FDA Breakthrough Therapy designation for non-cirrhotic MASH F2-F3. Ascletis reported positive Phase 3 acne results for denifanstat in China. Sagimet is exploring Phase 3 funding and will initiate a Phase 1 PK study of denifanstat plus resmetirom in H2 2025, and started a Phase 1 trial of second candidate TVB-3567 in June 2025.
Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.
The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.
FAQ
What is the current stock price of Sagimet Biosciences (SGMT)?
What is the market cap of Sagimet Biosciences (SGMT)?
